All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Calcineurin inhibitors can be used alongside donor regulatory T cells (Tregs) for the prevention of graft-versus-host disease (GvHD) in patients who undergo allogeneic hematopoietic cell transplantation (allo-HCT). Regulatory T cells restrain excessive immune responses in patients and have shown promise as a form of GvHD prophylaxis. However, it remains unclear if the addition of immunosuppressive prophylaxis, for example with single agent tacrolimus (TAC), adds any GvHD preventative benefit to the use of a Treg graft alone.
Here, we summarize an article by Bader et al.,1 published in Blood Advances, evaluating the use of T-reg graft vs Treg graft + TAC for the prevention of acute GvHD (aGvHD) (NCT01660607).
Table 1. Cumulative incidence of GvHD in patients who received Treg graft vs Treg graft + TAC*
|
Treg graft |
Treg graft + TAC |
p value |
---|---|---|---|
Grade 2─4 aGvHD |
58.3% |
8.3% |
p = 0.006 |
Grade 3─4 aGvHD |
17% |
0% |
p = 0.149 |
Moderate-to-severe cGvHD at 1 year |
28.4% |
0.0% |
p = 0.058 |
aGvHD, acute graft-versus-host disease; cGvHD, chronic GvHD; TAC, tacrolimus; Treg; T-regulatory cell. |
Key learnings |
|
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox